ArticleMedComm2026

Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies.

Rongcheng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.